Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company targets unmet medical needs in areas such as hematology, blood disorders, inflammation, immunology, and metabolic diseases. Key pipeline candidates include rusfertide, an injectable hepcidin mimetic in phase 3 clinical trials for polycythemia vera; icotrokinra (formerly JNJ-2113), an orally delivered investigational drug in phase 3 trials for plaque psoriasis and inflammatory diseases; and PN-943, an oral gut-restricted integrin antagonist that has completed phase 2 trials for ulcerative colitis. Additional programs encompass oral IL-17 antagonists like PN-881, obesity treatments, and iron metabolism disorders, advanced through internal efforts and collaborations with partners including Johnson & Johnson and Takeda. Protagonist Therapeutics Inc. plays a vital role in the biotechnology sector by pioneering oral peptide alternatives to injectable therapies for immune-mediated skin diseases and rare blood conditions. Founded in 2006 and headquartered in Newark, California, it focuses on advancing innovative treatments to improve patient outcomes in challenging therapeutic areas.